Dr Sofia Rivera talks to ecancer at ESMO 2024 about the phase three HypoG-01 study looking at hypofractionated radiation therapy for breast cancer.

The study has the potential to change the management of patients treated for breast cancer. The results, presented during a presidential session at the ESMO conference, demonstrate that a hypofractionated radiation therapy course of 15 sessions over 3 weeks is equivalent to a normofractionated radiation therapy of 25 sessions over 5 weeks for locoregional breast cancer.

HypoG-01 is the first global study to demonstrate this prospectively and randomly, making the three-week course a standard of care for all women with node-invasive breast cancer.